BTIG Lowers Remicade Outlook for Johnson & Johnson (JNJ); Affirms 'Neutral' Rating

Janssen Submits Application to the European Medicines Agency (EMA) to Expand Use of DARZALEX®▼ (daratumumab) to Include Combination with Standard of Care Regimens

Phase 3 data supporting submission suggests potential clinical benefit of daratumumab as a backbone therapy in combination with either a proteasome inhibitor (PI) or an immunomodulatory agent for relapsed multiple myeloma patients

BEERSE, Belgium--(BUSINESS WIRE)-- Janssen-Cilag International NV today announced the submission of a Type II variation application to the European Medicines Agency (EMA), seeking to broaden the existing marketing authorisation for the immunotherapy DARZALEX® (daratumumab) to include treatment of adult patients with relapsed multiple myeloma who have received at least one prior therapy. The expanded indication is based on daratumumab in combination with lenalidomide (an... More

Janssen Announces 25 Presentations at Upcoming ESC Congress 2016, Including New Clinical and Real-World Research on XARELTO® and Latest Findings from REVISIT-US

RARITAN, N.J., Aug. 22, 2016 /PRNewswire/ -- Janssen Pharmaceuticals, Inc., today announced that 25 abstracts have been accepted for presentation by Janssen and its development partner, Bayer, at the ESC Congress 2016, taking place August 27-31 in Rome, Italy. New real-world evidence from the EXPLORER research program, including latest findings from the REVISIT-US study, will address how XARELTO® (rivaroxaban), a non-vitamin K antagonist oral anticoagulant (NOAC), is performing in routine clinical practice. Also, the companies will unveil the design of the GALILEO trial, which seeks to address blood clot prevention for patients following successful transcatheter aortic valve replacement (TAVR).... More